Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of Baricitinib in Patients With Diabetic Kidney Disease

NCT01683409 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01683409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01683409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of Baricitinib in Patients With Diabetic Kidney Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2012
Completion date
November 30, 2014
Enrollment
130 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic kidney disease